Olga Mineeva, Chunying Li, Franco Giulianini, Simeon Häfliger, Vadim Bubes, Gunnar Raetsch, Samia Mora, Olga V Demler
{"title":"ASCVD患者新型剩余风险评分的开发和验证。","authors":"Olga Mineeva, Chunying Li, Franco Giulianini, Simeon Häfliger, Vadim Bubes, Gunnar Raetsch, Samia Mora, Olga V Demler","doi":"10.1016/j.jacadv.2025.102162","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite clinical need, personalized risk scores for established atherosclerotic cardiovascular disease (ASCVD) are scarce.</p><p><strong>Objectives: </strong>The objective of the study was to develop and validate 10-year residual risk scores for cardiovascular death in patients with established ASCVD.</p><p><strong>Methods: </strong>Prospective observational cohort study. Models developed and validated in U.K. Biobank (UKB) (baseline 2006-2010; follow-up through 2021) and externally validated in Mass General Brigham cohort (MGB) (baseline 2007; follow-up through 2018). Analyzed on October 2022-February 2024. Eligible participants had established ASCVD. Guideline-based clinical factors plus additional biomarkers and self-reported health ratings.</p><p><strong>Primary outcome: </strong>10-year cardiovascular death. Elastic-net Cox and gradient-boosted tree models. C statistics and goodness-of-fit assessed in holdout set.</p><p><strong>Results: </strong>UKB: 32,994 participants (mean age 61; 11,727 [35.5%] women; 2,660 [8.0%] cardiovascular deaths), with 9,899 (30%) randomly selected as a holdout validation set. MGB: 54,969 patients (mean age 71; 22,738 [41.4%] women; 6,927 [12.6%] cardiovascular deaths). Median follow-up: 10 years (IQR 10-10) in UKB; 9.4 years (5-10) in MGB. We developed 2 residual risk scores, RRS16 and RRS24, incorporating 16 and 24 algorithmically selected factors. RRS16 used routinely available factors; RRS24 also included self-reported health and additional biomarkers. RRS16 achieved C statistics of 0.752 (95% CI: 0.736-0.768) in UKB and 0.750 (0.744-0.756) in MGB, outperforming the 2018 the American Heart Association (AHA) guideline model (0.658 [0.642-0.674] in UKB, 0.580 [0.574-0.586] in MGB). RRS24 achieved 0.784 (0.768-0.800) in UKB. Both models well calibrated (P > 0.1). RRS16 calculator: https://mora.bwh.harvard.edu/rrs16/.</p><p><strong>Conclusions: </strong>RRS16 and RRS24 outperformed AHA guideline model in estimating the residual risk in patients with established ASCVD. Both are clinically applicable but require further validation in diverse populations.</p>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 11 Pt 1","pages":"102162"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and Validation of Novel Residual Risk Scores for Patients With ASCVD.\",\"authors\":\"Olga Mineeva, Chunying Li, Franco Giulianini, Simeon Häfliger, Vadim Bubes, Gunnar Raetsch, Samia Mora, Olga V Demler\",\"doi\":\"10.1016/j.jacadv.2025.102162\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Despite clinical need, personalized risk scores for established atherosclerotic cardiovascular disease (ASCVD) are scarce.</p><p><strong>Objectives: </strong>The objective of the study was to develop and validate 10-year residual risk scores for cardiovascular death in patients with established ASCVD.</p><p><strong>Methods: </strong>Prospective observational cohort study. Models developed and validated in U.K. Biobank (UKB) (baseline 2006-2010; follow-up through 2021) and externally validated in Mass General Brigham cohort (MGB) (baseline 2007; follow-up through 2018). Analyzed on October 2022-February 2024. Eligible participants had established ASCVD. Guideline-based clinical factors plus additional biomarkers and self-reported health ratings.</p><p><strong>Primary outcome: </strong>10-year cardiovascular death. Elastic-net Cox and gradient-boosted tree models. C statistics and goodness-of-fit assessed in holdout set.</p><p><strong>Results: </strong>UKB: 32,994 participants (mean age 61; 11,727 [35.5%] women; 2,660 [8.0%] cardiovascular deaths), with 9,899 (30%) randomly selected as a holdout validation set. MGB: 54,969 patients (mean age 71; 22,738 [41.4%] women; 6,927 [12.6%] cardiovascular deaths). Median follow-up: 10 years (IQR 10-10) in UKB; 9.4 years (5-10) in MGB. We developed 2 residual risk scores, RRS16 and RRS24, incorporating 16 and 24 algorithmically selected factors. RRS16 used routinely available factors; RRS24 also included self-reported health and additional biomarkers. RRS16 achieved C statistics of 0.752 (95% CI: 0.736-0.768) in UKB and 0.750 (0.744-0.756) in MGB, outperforming the 2018 the American Heart Association (AHA) guideline model (0.658 [0.642-0.674] in UKB, 0.580 [0.574-0.586] in MGB). RRS24 achieved 0.784 (0.768-0.800) in UKB. Both models well calibrated (P > 0.1). RRS16 calculator: https://mora.bwh.harvard.edu/rrs16/.</p><p><strong>Conclusions: </strong>RRS16 and RRS24 outperformed AHA guideline model in estimating the residual risk in patients with established ASCVD. Both are clinically applicable but require further validation in diverse populations.</p>\",\"PeriodicalId\":73527,\"journal\":{\"name\":\"JACC advances\",\"volume\":\"4 11 Pt 1\",\"pages\":\"102162\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jacadv.2025.102162\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jacadv.2025.102162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Development and Validation of Novel Residual Risk Scores for Patients With ASCVD.
Background: Despite clinical need, personalized risk scores for established atherosclerotic cardiovascular disease (ASCVD) are scarce.
Objectives: The objective of the study was to develop and validate 10-year residual risk scores for cardiovascular death in patients with established ASCVD.
Methods: Prospective observational cohort study. Models developed and validated in U.K. Biobank (UKB) (baseline 2006-2010; follow-up through 2021) and externally validated in Mass General Brigham cohort (MGB) (baseline 2007; follow-up through 2018). Analyzed on October 2022-February 2024. Eligible participants had established ASCVD. Guideline-based clinical factors plus additional biomarkers and self-reported health ratings.
Primary outcome: 10-year cardiovascular death. Elastic-net Cox and gradient-boosted tree models. C statistics and goodness-of-fit assessed in holdout set.
Results: UKB: 32,994 participants (mean age 61; 11,727 [35.5%] women; 2,660 [8.0%] cardiovascular deaths), with 9,899 (30%) randomly selected as a holdout validation set. MGB: 54,969 patients (mean age 71; 22,738 [41.4%] women; 6,927 [12.6%] cardiovascular deaths). Median follow-up: 10 years (IQR 10-10) in UKB; 9.4 years (5-10) in MGB. We developed 2 residual risk scores, RRS16 and RRS24, incorporating 16 and 24 algorithmically selected factors. RRS16 used routinely available factors; RRS24 also included self-reported health and additional biomarkers. RRS16 achieved C statistics of 0.752 (95% CI: 0.736-0.768) in UKB and 0.750 (0.744-0.756) in MGB, outperforming the 2018 the American Heart Association (AHA) guideline model (0.658 [0.642-0.674] in UKB, 0.580 [0.574-0.586] in MGB). RRS24 achieved 0.784 (0.768-0.800) in UKB. Both models well calibrated (P > 0.1). RRS16 calculator: https://mora.bwh.harvard.edu/rrs16/.
Conclusions: RRS16 and RRS24 outperformed AHA guideline model in estimating the residual risk in patients with established ASCVD. Both are clinically applicable but require further validation in diverse populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
